Expression of Sonic Hedgehog downstream genes is modified in rat embryos exposed in utero to a distal inhibitor of cholesterol biosynthesis.
Holoprosencephaly is a common developmental anomaly of the forebrain and midface, that has been associated with mutations in the Sonic Hedgehog gene, and with perturbations of cholesterol synthesis and metabolism in mammalian embryos. The study presented here was aimed to evaluate the functional relationship between these two causal agents in the genesis of the phenotype. Therefore, we used rat embryos exposed in utero to a distal inhibitor of cholesterol biosynthesis (AY9944) in which we analyzed different Shh-dependent processes, as evaluated by the expression of eight target genes. In addition, to delineate between the impact of cholesterol shortage and/or sterol precursors accumulation on the Shh signaling cascade we exposed rat embryos to AY9944 and we provided complementary diets rich in cholesterol and 7-DHC. At the early-somite stage we observed a reduction of Shh signaling in AY9944 treated embryos, resulting in the definition of a narrower ventral domain. Later in development this reduction of Shh signaling led to a complete interruption of the pathway in the rostral hindbrain and caudal midbrain. Other regions such as the forebrain and the spinal cord appeared less sensitive to the reduction of Shh signaling and interruption of the pathway was only observed in a subset of embryos. Finally, we did provide evidence that 7-DHC accumulation is compatible with normal activity of Shh, as long as cholesterol levels in embryonic tissue is sufficient.
Gofflot
F
F
Unit of Developmental Genetics, Université Catholique de Louvain, 73 Avenue E. Mounier, UCL-7382, B-1200, Bruxelles, Belgium. francoise.gofflot@gede.acl.ac.be
Gaoua
W
W
Bourguignon
L
L
Roux
C
C
Picard
J J
JJ
D000014:Abnormalities, Drug-Induced; D000818:Animals; D000924:Anticholesteremic Agents / Q000494:pharmacology*; D002784:Cholesterol / Q000502:physiology; D002791:Cholesterol, Dietary / Q000494:pharmacology; D000013:Congenital Abnormalities / Q000196:embryology / Q000235:genetics*; D003684:Dehydrocholesterols / Q000378:metabolism / Q000494:pharmacology; D004627:Embryonic Induction; D005314:Embryonic and Fetal Development / Q000187:drug effects / Q000502:physiology*; D005260:Female; D018507:Gene Expression Regulation, Developmental / Q000187:drug effects*; D053823:Hedgehog Proteins; D016142:Holoprosencephaly / Q000235:genetics; D006801:Humans; D017403:In Situ Hybridization; D011247:Pregnancy; D011506:Proteins / Q000235:genetics* / Q000378:metabolism; D051381:Rats; D015534:Trans-Activators; D001371:trans-1,4-Bis(2-chlorobenzaminomethyl)cyclohexane Dihydrochloride / Q000494:pharmacology*
D000924:Anticholesteremic Agents; D002791:Cholesterol, Dietary; D003684:Dehydrocholesterols; D053823:Hedgehog Proteins; D011506:Proteins; C509239:SHH protein, human; D015534:Trans-Activators; D001371:trans-1,4-Bis(2-chlorobenzaminomethyl)cyclohexane Dihydrochloride; D002784:Cholesterol; C016705:7-dehydrocholesterol